^
    1year
    Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting (AACR 2023)
    Approximately 10 peptides were synthesized per patient, and a mixture of these peptides was administered as 10 subcutaneous and intradermal vaccines over 27 weeks in combination with poly-ICLC and helper Tetanus peptide as adjuvants. We have established a platform for generating personalized neoantigen vaccines. 100% of the vaccinated patients developed an immune response specific to the vaccine neoantigens predicted by OpenVax. Subjects who received treatment experienced mild Grade 1 or 2 adverse reactions as per the CTEP v 4.0 NCI CTCAE.
    P1 data • Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • PGV-001
    4years
    [VIRTUAL] PGV-001: A phase I trial of a multipeptide personalized neoantigen vaccine in the adjuvant setting (AACR-II 2020)
    The vaccine was administered over the course of 6 months, given in combination with poly-ICLC as the adjuvant. The PGV-001 personalized neoantigen vaccine was successfully administered to 13 patients, where each patient’s neoantigen load was adequate for vaccine synthesis. While we have demonstrated the computational feasibility of identification of neoantigens for inclusion in the PGV-001 genomic vaccine, clinical outcomes will be reported separately.
    Clinical • P1 data
    |
    CD8 (cluster of differentiation 8)
    |
    Hiltonol (poly-ICLC) • PGV-001